<?xml version='1.0' encoding='UTF-8'?>
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id>
      <journal-title-group>
        <journal-title>Nature and Science of Sleep</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1179-1608</issn>
      <publisher>
        <publisher-name>Dove Medical Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23616702</article-id>
      <article-id pub-id-type="pmc">3630938</article-id>
      <article-id pub-id-type="publisher-id">nss-2-095</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Armodafinil in the treatment of excessive sleepiness</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rosenberg</surname>
            <given-names>Russell</given-names>
          </name>
          <xref ref-type="aff" rid="af1-nss-2-095">1</xref>
          <xref ref-type="corresp" rid="c1-nss-2-095"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bogan</surname>
            <given-names>Richard</given-names>
          </name>
          <xref ref-type="aff" rid="af2-nss-2-095">2</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-nss-2-095"><label>1</label>NeuroTrials Research, Atlanta, Georgia, USA</aff>
      <aff id="af2-nss-2-095"><label>2</label>SleepMed of South Carolina, Columbia, South Carolina, USA</aff>
      <author-notes>
        <corresp id="c1-nss-2-095">Correspondence: Russell Rosenberg, NeuroTrials Research, 1100 Johnson Ferry Rd, Ste 420, Atlanta, GA 30342, USA Tel +1 678 651 2000 Fax +1 678 651 2025 email <email>russell.rosenberg@atlantasleep.com</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>08</day>
        <month>7</month>
        <year>2010</year>
      </pub-date>
      <volume>2</volume>
      <fpage>95</fpage>
      <lpage>105</lpage>
      <permissions>
        <copyright-statement>© 2010 Rosenberg and Bogan, publisher and licensee Dove Medical Press Ltd</copyright-statement>
        <copyright-year>2010</copyright-year>
        <license>
          <license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p><citation_analysis attribute="positive">Excessive sleepiness (ES) is a widespread condition, commonly the result of a sleep/ wake disorder such as obstructive sleep apnea (OSA), shift-work disorder (SWD), or narcolepsy. ES poses significant health and safety concerns in patients. Numerous interventions are available to treat the underlying causes of ES and ES itself, including behavioral measures, mechanical devices, and pharmacologic agents. This review explores the evidence supporting the use of armodafinil to treat ES associated with OSA, SWD, and narcolepsy. Armodafinil is an oral non-amphetamine wake-promoting agent, the </citation_analysis><citation_analysis attribute="positive"><italic>R</italic></citation_analysis><citation_analysis attribute="positive">-isomer of racemic modafinil. Armodafinil and modafinil share many clinical and pharmacologic properties and are distinct from central nervous system stimulants; however, the mechanisms of action of modafinil and armodafinil are poorly characterized. Compared with modafinil, the wake-promoting effects of armodafinil persist later in the day. It is for this reason that armodafinil may be a particularly appropriate therapy for patients with persistent ES due to OSA, SWD, or narcolepsy.</citation_analysis></p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>excessive sleepiness</kwd>
        <kwd>obstructive sleep apnea</kwd>
        <kwd>shift-work disorder</kwd>
        <kwd>narcolepsy</kwd>
        <kwd>wakefulness-promoting agent</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p><citation_analysis attribute="neither">Excessive sleepiness (ES) is common and may occur as a consequence of a number of sleep/wake disorders including obstructive sleep apnea (OSA), shift-work disorder (SWD), narcolepsy, and jet lag. Although the full extent of its prevalence has not been established, ES is known to be widespread, in part because of the large number of people who are required to perform shift work, work for prolonged periods, or regularly participate in transmeridian fight.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b1-nss-2-095">1</xref></citation_analysis><citation_analysis attribute="neither"> Findings from the National Sleep Foundation’s 2008 Sleep in America Poll</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b2-nss-2-095">2</xref></citation_analysis><citation_analysis attribute="negative"> point to a large proportion of working Americans being affected by a lack of sleep, with 15% of the 1000 respondents having been diagnosed with a sleep/wake disorder. This poll also revealed that 29% of respondents had slept or been drowsy at work in the past month and that 36% had fallen asleep while driving in the past year.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b2-nss-2-095">2</xref></citation_analysis></p>
      <p><citation_analysis attribute="negative">ES may also arise because of insufficient night-time sleep due to behavioral issues (eg, self-imposed sleep deprivation or poor sleep hygiene), psychiatric conditions, medication, or medical conditions other than sleep/wake disorders.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b3-nss-2-095">3</xref></citation_analysis><citation_analysis attribute="neither"> Sleep hygiene refers to elements intended to create a mental and environmental state conducive to sleep, eg, a regular sleep/wake pattern, avoidance of stimulants such as caffeine and nicotine close to bedtime, and having a quiet, peaceful place to sleep.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b4-nss-2-095">4</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b5-nss-2-095">5</xref></citation_analysis><citation_analysis attribute="neither"> The co-existence of psychiatric disorders and ES is common.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b6-nss-2-095">6</xref></citation_analysis><citation_analysis attribute="positive"> For example, depression often interferes with sleep behavior and thus the quality of sleep. The side effects of a wide variety of medications, such as benzodiazepines and antihistamines, can cause ES.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b3-nss-2-095">3</xref></citation_analysis><citation_analysis attribute="neither"> A number of medical conditions can affect the duration and quality of sleep, such as those that interfere with breathing (eg, nasal congestion and chronic obstructive pulmonary disease), Parkinson’s disease, movement disorders, and chronic pain syndromes.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b7-nss-2-095">7</xref></citation_analysis><citation_analysis attribute="neither"> Both quality and quantity of sleep are important factors in ensuring that an individual feels rested and alert and poor sleep quality in particular has been found to be related to the development of ES.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b8-nss-2-095">8</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">This review will discuss the prevalence and management of ES before moving on to its main focus – the use of the wake-promoting agent armodafinil in the treatment of ES. Armodafinil has been approved in the United States for the treatment of patients with ES associated with treated OSA, SWD, and narcolepsy.</citation_analysis></p>
    </sec>
    <sec>
      <title>Consequences of ES</title>
      <p><citation_analysis attribute="neither">ES affects not only patients’ health but also their ability to work and drive safely and the extent to which they can function and enjoy day-to-day living.</citation_analysis></p>
      <sec>
        <title>Clinical consequences</title>
        <p><citation_analysis attribute="neither">ES is associated with increased rates of cardiovascular mortality, myocardial infarction, and congestive heart failure.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b9-nss-2-095">9</xref></citation_analysis><citation_analysis attribute="negative"> Moreover, patients with OSA and associated ES are at a higher risk of developing ischemic heart disease than patients who have OSA in isolation.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b10-nss-2-095">10</xref></citation_analysis><citation_analysis attribute="positive"> Patients with ES are also more likely to develop diabetes than those without ES and, on average, have a higher body mass index; both diabetes and high BMI are characteristics of metabolic syndrome.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b11-nss-2-095">11</xref></citation_analysis><citation_analysis attribute="negative"> The relationship between OSA, ES, and metabolic syndrome is complex; however, it is thought that these individual factors interact and exacerbate each other, putting the patient at greater risk for further complications.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b11-nss-2-095">11</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">ES can lead to significant cognitive sequelae, affecting both attention and memory.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b12-nss-2-095">12</xref></citation_analysis><citation_analysis attribute="neither"> Patients with ES associated with OSA or shift work are particularly susceptible to reductions in cognitive functioning.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b13-nss-2-095">13</xref></citation_analysis><citation_analysis attribute="neither"> Depression and ES have a complex and reciprocal relationship: sleep disruption associated with depression can lead patients to experience ES, while mental, social, and work issues caused by persistent ES can also trigger depression.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b11-nss-2-095">11</xref></citation_analysis></p>
      </sec>
      <sec>
        <title>Workplace and driving consequences</title>
        <p><citation_analysis attribute="negative">Individuals with ES associated with OSA are at an increased risk for recent work disability (adjusted odds ratio 13.7; 95% confidence interval [CI], 3.9–48.0) or a work role change due to a lack of coping/poor performance (odds ratio 3.6; 95% CI, 1.1–12.0) compared with individuals without this sleep disorder.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b14-nss-2-095">14</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, the occurrence of absenteeism is elevated in individuals with ES and is further exacerbated by shift work.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b15-nss-2-095">15</xref></citation_analysis><citation_analysis attribute="positive"> According to a survey of occupational accidents occurring in the United States in 1988, ES was implicated in 52.5% of all work-related accidents, amounting to an estimated cost of $24.7 billion (based on 1994 calculations; $36.1 billion when adjusted to 2009 values).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b16-nss-2-095">16</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">There is substantial evidence that ES contributes to many road traffic crashes, with a survey conducted in the UK revealing that 17% of collisions resulting in injury or death are sleep related.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b17-nss-2-095">17</xref></citation_analysis><citation_analysis attribute="positive"> This survey also revealed that sleep-related collisions are approximately 50% more likely to result in death or serious injury than other road traffic crashes.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b17-nss-2-095">17</xref></citation_analysis><citation_analysis attribute="neither"> A review of traffic safety in relation to sleep/wake disorders and ES listed changes in attention and information processing, changes in sensation and perception, “highway hypnosis,” and microsleeping as consequences of ES that led to poor driver performance.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b18-nss-2-095">18</xref></citation_analysis><citation_analysis attribute="positive"> A combined field and laboratory study by the US Department of Transportation has revealed that many long-haul commercial drivers nap during shiftwork hours and spend a significant part of their time at the wheel in a state of sleep deprivation.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b19-nss-2-095">19</xref></citation_analysis></p>
      </sec>
      <sec>
        <title>Quality of life</title>
        <p><citation_analysis attribute="neither">A recent analysis of 1892 adults with untreated OSA revealed that quality of life (QOL) not only worsened with the severity of the condition, but that it was also at its lowest in those with ES.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b20-nss-2-095">20</xref></citation_analysis><citation_analysis attribute="neither"> In this study, all domains of the Medical Outcomes Study Short-Form (36-item) Health Survey (SF-36) were significantly negatively affected by ES (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.05).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b20-nss-2-095">20</xref></citation_analysis><citation_analysis attribute="neither"> ES is also detrimental to QOL in patients with narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b21-nss-2-095">21</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b22-nss-2-095">22</xref></citation_analysis><citation_analysis attribute="positive"> In particular, patients with narcolepsy and cataplexy report that ES has a significant negative impact on the role physical subscale of the SF-36.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b22-nss-2-095">22</xref></citation_analysis><citation_analysis attribute="neither"> Earlier studies have also highlighted the impact of ES on patients’ everyday lives, reporting that patients with sleep-disordered breathing and ES have lower scores on all subscales of the SF-36 when compared with patients who are not excessively sleepy.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b23-nss-2-095">23</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b26-nss-2-095">26</xref></citation_analysis></p>
      </sec>
    </sec>
    <sec>
      <title>Management of ES</title>
      <p><citation_analysis attribute="neither">ES is an underrecognized and undertreated condition, in part because it may not be perceived as a serious problem and hence is not disclosed by patients.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b3-nss-2-095">3</xref></citation_analysis><citation_analysis attribute="negative"> Patients may not recognize their ES at all or describe it to their physician as tiredness, fatigue, difficulty concentrating, or a lack of energy.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b27-nss-2-095">27</xref></citation_analysis><citation_analysis attribute="negative"> In addition, ES can be misdiagnosed as depression owing to shared signs such as a lack of motivation, memory disturbances, and diminished interest in activities of daily living.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b3-nss-2-095">3</xref></citation_analysis><citation_analysis attribute="positive"> To aid in the recognition of ES and potential causative sleep/wake disorders, physicians can ask questions regarding the patient’s sleep quality, assess alertness using simple subjective measures, such as the Epworth Sleepiness Scale (ESS), or use objective measures of ES, such as the Multiple Sleep Latency Test (MSLT) or Maintenance of Wakefulness Test (MWT).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b28-nss-2-095">28</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b30-nss-2-095">30</xref></citation_analysis><citation_analysis attribute="neither"> The ESS is the most widely adopted instrument and is useful for identifying ES in clinical practice, particularly in the primary care setting, and is appropriate for monitoring self-reported responses to management/ treatment approaches.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b28-nss-2-095">28</xref></citation_analysis><citation_analysis attribute="neither"> The MSLT and MWT are most often used by sleep specialists and measure a patient’s ability to fall asleep or remain awake, respectively.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b29-nss-2-095">29</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b30-nss-2-095">30</xref></citation_analysis><citation_analysis attribute="neither"> Additional information that a healthcare professional might seek for the identification of ES includes the following: the number of hours of sleep that the patient gets on most nights; whether the patient snores or holds their breath during sleep; whether the patients wake up feeling refreshed most mornings; whether the patient is sleepy or fatigued during waking hours; and whether the patient works night or rotating shifts.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Strategies for the management of ES should begin with an initial assessment to identify the cause of ES and, where possible, to treat any underlying disorder. In many cases, all that may be required is education regarding proper sleep hygiene, in particular, maintaining a regular schedule of activities.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b5-nss-2-095">5</xref></citation_analysis><citation_analysis attribute="neither"> However, mechanical interventions and/or medication are often necessary to address conditions such as OSA, SWD, or narcolepsy.</citation_analysis></p>
      <sec>
        <title>Management of sleep/wake disorders causative of ES</title>
        <sec>
          <title>Obstructive sleep apnea</title>
          <p><citation_analysis attribute="neither">OSA is characterized by intermittent full or partial obstruction of the upper airway during sleep leading to abnormal breathing and repetitive episodes of arousal.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b31-nss-2-095">31</xref></citation_analysis><citation_analysis attribute="positive"> OSA with associated ES is the most frequently reported sleep-related breathing disorder, with an estimated prevalence in the United States of 4% and 2% in middle-aged men and women, respectively.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b32-nss-2-095">32</xref></citation_analysis><citation_analysis attribute="neither"> Individuals with OSA complain of unrefreshing sleep, ES during the day, low mood, and an inability to concentrate.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b33-nss-2-095">33</xref></citation_analysis></p>
          <p><citation_analysis attribute="positive">Continuous positive airway pressure (CPAP) therapy is the gold standard treatment for OSA. The CPAP device ensures that the airway remains open, reducing the arousals from sleep that can occur as a consequence of airway collapse and reduced blood oxygen levels.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b34-nss-2-095">34</xref></citation_analysis><citation_analysis attribute="positive"> Unfortunately, objective ES (as measured using the MSLT) persists in approximately 50% of patients, even when abnormal respiratory events are optimally treated with ≥6 hours of CPAP per night.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b35-nss-2-095">35</xref></citation_analysis><citation_analysis attribute="neither"> The wakefulness-promoting agent modafinil is recommended by the American Academy of Sleep Medicine (AASM) for the treatment of residual ES in patients with treated OSA.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b36-nss-2-095">36</xref></citation_analysis><citation_analysis attribute="neither"> Modafinil and its enantiomer armodafinil are approved by the US Food and Drug Administration (FDA) for this indication, based on the results of several large-scale clinical trials.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b37-nss-2-095">37</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b41-nss-2-095">41</xref></citation_analysis><citation_analysis attribute="positive"> As armodafinil is a comparatively new medication, it has not yet been incorporated into AASM guidelines for the treatment of ES associated with treated OSA. Stimulants, such as amphetamines, reverse the daytime somnolence seen in some patients on CPAP therapy; however, these agents carry a potential risk for abuse and cardiovascular sequelae and further evidence is required before they can be recommended in this indication.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b33-nss-2-095">33</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b36-nss-2-095">36</xref></citation_analysis></p>
        </sec>
        <sec>
          <title>Shift-work disorder</title>
          <p><citation_analysis attribute="neither">The homeostatic drive for sleep intensifies with increasing time since the last rest period and is offset during daylight hours by circadian wake-promoting processes. Shift-work schedules cause misalignment of the sleep/wake pattern so that the homeostatic drive for sleep is no longer counteracted by the body’s endogenous circadian rhythm.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b31-nss-2-095">31</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b42-nss-2-095">42</xref></citation_analysis><citation_analysis attribute="neither"> SWD is diagnosed by persistent insomnia when trying to sleep and/or ES when trying to stay awake – these symptoms must coincide with the affected individual’s working shifts.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b31-nss-2-095">31</xref></citation_analysis><citation_analysis attribute="neither"> Approximately 22 million Americans regularly work night, early morning, or rotating shifts</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b43-nss-2-095">43</xref></citation_analysis><citation_analysis attribute="positive"> and SWD has become a common – although underrecognized – condition as a result. In a US study, 44.8% of night-shift workers and 35.8% of rotating-shift workers were reported to have SWD (as assessed by an ESS score of ≥10), which suggests that up to 45% of individuals who work shifts may be at risk of developing SWD.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b15-nss-2-095">15</xref></citation_analysis><citation_analysis attribute="positive"> More recently, a study of United Kingdom North Sea oil rig workers has reported that 23% of shift workers have SWD.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b44-nss-2-095">44</xref></citation_analysis></p>
          <p><citation_analysis attribute="neither">The treatment of SWD encompasses a number of interventions including nonpharmacologic measures, such as improving sleep hygiene, light therapy, and planned nap times.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b42-nss-2-095">42</xref></citation_analysis><citation_analysis attribute="neither"> Modafinil and armodafinil are FDA approved for the treatment of ES associated with SWD. These non-stimulant wakefulness-promoting agents significantly increased sleep latencies in randomized controlled trials conducted specifically in patients with SWD.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b45-nss-2-095">45</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b47-nss-2-095">47</xref></citation_analysis><citation_analysis attribute="neither"> Other pharmacologic options, including melatonin and hypnotics such as zolpidem (to improve daytime sleep) and stimulants such as methamphetamine (to improve night-time alertness), have had varying degrees of success in promoting sleep or wake in shift workers.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b1-nss-2-095">1</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b48-nss-2-095">48</xref></citation_analysis><citation_analysis attribute="neither"> However, studies of these agents in SWD are limited, making it difficult to draw firm conclusions as to their utility in patients with this sleep disorder.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b42-nss-2-095">42</xref></citation_analysis></p>
        </sec>
        <sec>
          <title>Narcolepsy</title>
          <p><citation_analysis attribute="neither">Narcolepsy occurs in &lt;1% of individuals in the United States</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b49-nss-2-095">49</xref></citation_analysis><citation_analysis attribute="neither"> and is characterized by ES that varies in intensity throughout the day, such that the affected individual has to take frequent naps.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b31-nss-2-095">31</xref></citation_analysis><citation_analysis attribute="negative"> Indeed, narcolepsy often results in unanticipated sleep episodes lasting from a few seconds to several minutes during periods of reduced stimulation.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b3-nss-2-095">3</xref></citation_analysis></p>
          <p><citation_analysis attribute="neither">The intrinsic dysfunction in sleep regulation that causes ES in narcolepsy often requires pharmacotherapy to enhance wakefulness. Methylphenidate and dextroamphetamine are approved in this indication, although these medications have the potential for abuse and their use should therefore be monitored closely.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b50-nss-2-095">50</xref></citation_analysis><citation_analysis attribute="positive"> Sodium oxybate has been shown to significantly reduce ES and cataplexy in patients with narcolepsy in randomized clinical trials and it is the only FDA-approved medication for the treatment of both of these symptoms.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b51-nss-2-095">51</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b54-nss-2-095">54</xref></citation_analysis><citation_analysis attribute="positive"> Modafinil and armodafinil have been shown to address ES in patients with narcolepsy in randomized controlled trials</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b57-nss-2-095">57</xref></citation_analysis><citation_analysis attribute="neither"> and are approved by the FDA for this indication.</citation_analysis></p>
        </sec>
      </sec>
    </sec>
    <sec>
      <title>Armodafinil</title>
      <p><citation_analysis attribute="neither">Armodafinil and its use in the three indications described above will be the focus of the remainder of this article.</citation_analysis></p>
      <sec>
        <title>Pharmacology</title>
        <p><citation_analysis attribute="neither">Armodafinil (2-[</citation_analysis><citation_analysis attribute="positive"><italic>R</italic></citation_analysis><citation_analysis attribute="neither">-(diphenylmethyl)sulfinyl]acetamide; </citation_analysis><citation_analysis attribute="positive"><xref ref-type="fig" rid="f1-nss-2-095">Figure 1</xref></citation_analysis><citation_analysis attribute="neither">) is the </citation_analysis><citation_analysis attribute="positive"><italic>R</italic></citation_analysis><citation_analysis attribute="neither">-enantiomer of racemic modafinil and shares many of the properties and characteristics of modafinil. Like modafinil, armodafinil is an orally administered wake-promoting agent that is clinically and pharmacologically distinct from central nervous system stimulants.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b58-nss-2-095">58</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b59-nss-2-095">59</xref></citation_analysis></p>
        <sec>
          <title>Pharmacodynamics</title>
          <p><citation_analysis attribute="positive">The modes of action of armodafinil and modafinil are currently not fully understood, although it is likely that they involve selective effects on catecholaminergic signaling in the central nervous system via dopaminergic, noradrenergic, and serotonergic receptors.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b60-nss-2-095">60</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b62-nss-2-095">62</xref></citation_analysis><citation_analysis attribute="positive"> These effects are not well defined and despite </citation_analysis><citation_analysis attribute="positive"><italic>ex-vivo</italic></citation_analysis><citation_analysis attribute="neither"> assays showing binding of modafinil to the dopamine transporter and inhibition of dopamine reuptake, modafinil is not a direct or an indirect dopamine receptor agonist.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b63-nss-2-095">63</xref></citation_analysis><citation_analysis attribute="neither"> Hypocretin (or orexin)-producing neurons within the hypothalamus (postulated as preventing inappropriate changes in consciousness) are believed to be activated by modafinil to release dopamine and norepinephrine to promote wakefulness,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b64-nss-2-095">64</xref></citation_analysis><citation_analysis attribute="neither"> and this activity may also account for the observed clinical effect of armodafinil.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b61-nss-2-095">61</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b62-nss-2-095">62</xref></citation_analysis><citation_analysis attribute="neither"> Furthermore, modafinil may potentiate wakefulness by increasing electrical coupling at gap junctions between neurons.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b65-nss-2-095">65</xref></citation_analysis></p>
        </sec>
        <sec>
          <title>Pharmacokinetics</title>
          <p><citation_analysis attribute="neither">A 200 mg dose of armodafinil, when administered orally, is readily absorbed, with a maximum plasma drug concentration of 5.44 ± 1.64 μg/mL being achieved in approximately 2 hours.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b66-nss-2-095">66</xref></citation_analysis><citation_analysis attribute="neither"> These values are comparable with those for modafinil (</citation_analysis><citation_analysis attribute="positive"><xref ref-type="table" rid="t1-nss-2-095">Table 1</xref></citation_analysis><citation_analysis attribute="neither">). With once-daily dosing, armodafinil reaches its steady state after approximately 7 days.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b67-nss-2-095">67</xref></citation_analysis><citation_analysis attribute="neither"> The bioavailability of armodafinil is unaffected by food, although the rate of absorption is delayed by approximately 2–4 hours when armodafinil is taken postprandially.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b67-nss-2-095">67</xref></citation_analysis><citation_analysis attribute="neither"> Armodafinil is widely distributed outside the vascular system, but it does not have a high affinity for tissues.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b67-nss-2-095">67</xref></citation_analysis><citation_analysis attribute="neither"> It is unlikely to interact with highly protein-bound drugs, although it does bind with albumin to a moderate degree.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b63-nss-2-095">63</xref></citation_analysis></p>
          <p><citation_analysis attribute="neither">Armodafinil is metabolized by amide hydrolysis followed by sulfone formation via the cytochrome P450 (CYP) 3A4/5 enzyme pathway.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b63-nss-2-095">63</xref></citation_analysis><citation_analysis attribute="neither"> Dosage adjustment to sustain clinical efficacy may be necessary if patients are receiving concomitant medications that are also metabolized via this pathway (eg, steroidal contraceptives, cyclosporine, midazolam, and triazolam).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b63-nss-2-095">63</xref></citation_analysis><citation_analysis attribute="neither"> Like modafinil, armodafinil moderately inhibits the activity of CYP2C19, and medications that are metabolized via this enzyme (eg, diazepam) may display prolonged elimination, requiring lower doses of these agents to be administered when given concomitantly with armodafinil.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b68-nss-2-095">68</xref></citation_analysis></p>
          <p><citation_analysis attribute="neither">Elimination of armodafinil is monophasic with a mean elimination half-life of approximately 15 hours.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b67-nss-2-095">67</xref></citation_analysis><citation_analysis attribute="neither"> This contrasts with the elimination half-life of the </citation_analysis><citation_analysis attribute="positive"><italic>S</italic></citation_analysis><citation_analysis attribute="neither">-enantiomer, which is approximately three- to fourfold shorter than that of armodafinil and is responsible for racemic modafinil’s biphasic elimination profile. As a consequence of their different elimination profiles, armodafinil is present at higher concentrations than modafinil from 4–6 hours after administration.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b67-nss-2-095">67</xref></citation_analysis><citation_analysis attribute="neither"> Greater systemic availability of armodafinil compared with modafinil on a milligram-by-milligram basis (as indicated by a markedly greater area under the plasma drug concentration–time curve [</citation_analysis><citation_analysis attribute="positive"><xref ref-type="table" rid="t1-nss-2-095">Table 1</xref></citation_analysis><citation_analysis attribute="positive">]) may result in improved wakefulness later in the day in individuals with ES.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b66-nss-2-095">66</xref></citation_analysis></p>
          <p><citation_analysis attribute="neither">Dose reductions of armodafinil should be considered in patients with severe hepatic impairment owing to a reduction in observed oral clearance and an increase in the steady-state concentration of modafinil in this patient group.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b63-nss-2-095">63</xref></citation_analysis><citation_analysis attribute="neither"> Similarly, dose reductions should be considered in elderly patients in whom elimination may be delayed.</citation_analysis></p>
        </sec>
      </sec>
      <sec>
        <title>Efficacy of armodafinil</title>
        <p><citation_analysis attribute="neither">In preclinical studies, a rat model of sleep deprivation was used to explore the efficacy of armodafinil in comparison with the stimulant D-methamphetamine for promoting wakefulness.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b69-nss-2-095">69</xref></citation_analysis><citation_analysis attribute="neither"> The agents had equivalent wakefulness-promoting effects, as measured by their impact on sleep/wake patterns and body temperature. However, unlike d-methamphetamine, armodafinil did not induce symptoms of sleep deprivation such as acute rebound hypersomnolence.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b69-nss-2-095">69</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">To date, the only head-to-head study of armodafinil and modafinil was performed using healthy subjects.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b70-nss-2-095">70</xref></citation_analysis><citation_analysis attribute="neither"> Based on direct comparison of their pharmacokinetic/pharmacodynamic profiles, the prolonged half-life of armodafinil may be associated with improved wakefulness and sustained attention for a longer time after dosing than modafinil.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b70-nss-2-095">70</xref></citation_analysis><citation_analysis attribute="positive"> When administered as single doses to sleep-deprived healthy volunteers, both armodafinil and modafinil demonstrated significant wake fulness-promoting effects compared with placebo.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b70-nss-2-095">70</xref></citation_analysis><citation_analysis attribute="positive"> Using the MWT to measure sustained wakefulness and the Psychomotor Vigilance Task to measure sustained attention (ie, vigilance and reaction time), armodafinil and modafinil had significant positive effects on these parameters </citation_analysis><citation_analysis attribute="positive"><italic>(P</italic></citation_analysis><citation_analysis attribute="positive"><bold><italic>&lt;</italic></bold></citation_analysis><citation_analysis attribute="neither"> 0.0001 for both agents in both tests). However, compared with modafinil, armodafinil treatment resulted in fewer lapses in wakefulness and attention between 6 and 13.5 hours after administration, indicating that armodafinil may have comparatively prolonged effects.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b70-nss-2-095">70</xref></citation_analysis><citation_analysis attribute="neither"> Armodafinil may therefore represent a useful pharmacologic option for patients with ES associated with OSA, SWD, or narcolepsy who wish to stave off sleepiness for long periods.</citation_analysis></p>
        <sec>
          <title>Armodafinil for the treatment of ES associated with OSA</title>
          <p><citation_analysis attribute="neither">Two Phase 3 studies, which together randomized &gt;650 patients with OSA to treatment, have compared the efficacy and safety of armodafinil and placebo (</citation_analysis><citation_analysis attribute="positive"><xref ref-type="table" rid="t2-nss-2-095">Table 2</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b38-nss-2-095">38</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b39-nss-2-095">39</xref></citation_analysis><citation_analysis attribute="neither"> The patients enrolled in these studies had residual ES despite use of appropriately titrated CPAP therapy and were randomized to receive armodafinil 150 mg/day or placebo</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b38-nss-2-095">38</xref></citation_analysis><citation_analysis attribute="neither"> or armodafinil 150 or 250 mg/day or placebo.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b39-nss-2-095">39</xref></citation_analysis><citation_analysis attribute="positive"> The results of these studies have also been reported in a combined analysis.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis></p>
          <p><citation_analysis attribute="positive">Armodafinil was associated with a significant increase in mean sleep latency from baseline to the final visit at week 12 as measured using the MWT in all studies. In the study by Roth et al,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b39-nss-2-095">39</xref></citation_analysis><citation_analysis attribute="neither"> the mean change in sleep latency at the final visit was +1.9 minutes with armodafinil vs −1.7 minutes in patients given placebo </citation_analysis><citation_analysis attribute="positive"><italic>(P</italic></citation_analysis><citation_analysis attribute="positive"><bold><italic>&lt;</italic></bold></citation_analysis><citation_analysis attribute="neither"> 0.001). In the study conducted by Hirshkowitz et al,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b38-nss-2-095">38</xref></citation_analysis><citation_analysis attribute="neither"> patients receiving armodafinil experienced an increase in sleep latency of +2.3 minutes vs − 1.3 minutes in those given placebo </citation_analysis><citation_analysis attribute="positive"><italic>(P</italic></citation_analysis><citation_analysis attribute="positive"><bold><italic>&lt;</italic></bold></citation_analysis><citation_analysis attribute="neither"> 0.001). The combined analysis</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="positive"> reported that sleep latency increased by 2.0 minutes in patients administered armodafinil and decreased by 1.5 minutes in patients given placebo </citation_analysis><citation_analysis attribute="positive"><italic>(P</italic></citation_analysis><citation_analysis attribute="positive"><bold><italic>&lt;</italic></bold></citation_analysis><citation_analysis attribute="neither"> 0.0001; </citation_analysis><citation_analysis attribute="positive"><xref ref-type="table" rid="t2-nss-2-095">Table 2</xref></citation_analysis><citation_analysis attribute="positive">). Nighttime sleep was not adversely affected by armodafinil and patients’ compliance with CPAP therapy was high (a mean of approximately 7 hours/night). In addition, armodafinil had sustained benefits late in the waking day compared with placebo, as demonstrated by higher MWT scores at 15:00, 17:00, and 19:00 hours.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis></p>
          <p><citation_analysis attribute="positive">Improrements in patients’ clinical condition (evaluated using the Clinical Global Impression of Change scale [CGI-C]) were significantly greater in the armodafinil-treated group than in the placebo group </citation_analysis><citation_analysis attribute="positive"><italic>(P</italic></citation_analysis><citation_analysis attribute="positive"><bold><italic>&lt;</italic></bold></citation_analysis><citation_analysis attribute="neither"> 0.001) at all timepoints in the study of patients with OSA performed by Roth et al.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b39-nss-2-095">39</xref></citation_analysis><citation_analysis attribute="neither"> Similarly in the second OSA study conducted by Hirshkowitz et al,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b38-nss-2-095">38</xref></citation_analysis><citation_analysis attribute="neither"> the proportion of patients with at least minimal improvement in their clinical condition at the final visit was significantly higher in the armodafinil group compared with the placebo group (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.01).</citation_analysis></p>
          <p><citation_analysis attribute="neither">Cognitive performance was significantly improved with armodafinil compared with placebo in patients with OSA.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="neither"> The Cognitive Drug Research battery of tests was used to assess cognitive performance (memory and attention) at six timepoints during the day; the mean (± standard deviation) change from baseline in quality of long-term episodic secondary memory at the final visit was 10.2 (±31.7) units for the armodafinil group compared with −0.7 (±46.3) units for the placebo group (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.01).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis></p>
        </sec>
        <sec sec-type="subjects">
          <title>Armodafinil for the treatment of ES in patients with SWD</title>
          <p><citation_analysis attribute="positive">Armodafinil displayed significant benefits compared with placebo in a 12-week phase 3, randomized, double-blind, multicenter study of 245 patients with SWD (</citation_analysis><citation_analysis attribute="positive"><xref ref-type="table" rid="t2-nss-2-095">Table 2</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="positive"> Subjects included in this study were permanent or rotating night-shift workers with SWD who worked $5 nights per month, had a mean sleep latency of ≤6 min (as assessed using the MSLT), and had experienced ES during night shifts for ≥3 months.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis></p>
          <p><citation_analysis attribute="neither">Patients in this study had baseline mean sleep latencies of 2.3 and 2.4 minutes in the armodafinil and placebo groups, respectively; both values indicate severe sleepiness. At the end of the study, patients in the armodafinil group had significantly increased sleep latencies compared with the placebo group (3.1 vs 0.4 minutes, respectively; </citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="neither"> At the final visit, CGI-Improvement ratings were improved in a significantly greater proportion of patients in the armodafinil group compared with the placebo group (79% vs 59%, respectively; </citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> = 0.001).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="neither"> In addition, at the final visit, armodafinil significantly improved the quality of episodic secondary memory and the power and continuity of attention compared with placebo (all </citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> ≤ 0.001).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis></p>
        </sec>
        <sec sec-type="subjects">
          <title>Armodafinil for ES in patients with narcolepsy</title>
          <p><citation_analysis attribute="positive">The efficacy and safety of armodafinil for the treatment of ES in narcolepsy were demonstrated in a phase 3, placebo-controlled study of 194 patients (</citation_analysis><citation_analysis attribute="positive"><xref ref-type="table" rid="t2-nss-2-095">Table 2</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="neither"> In this study, patients were randomized to receive armodafinil 150 or 250 mg/day or placebo for 12 weeks.</citation_analysis></p>
          <p><citation_analysis attribute="positive">Daytime (09:00–15:00 hours) sleep tendency assessed using the MWT was found to be significantly improved with armodafinil (+1.9 minutes for both armodafinil groups combined) relative to placebo (−1.9 minutes; </citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="positive"> &lt; 0.01). These benefits were sustained late in the waking day (15:00–19:00 hours) as demonstrated by sleep latency improvements from baseline of 1.6 minutes for both armodafinil groups combined, while a reduction of 1.2 minutes was observed in patients in the placebo group (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.05 vs armodafinil).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis></p>
          <p><citation_analysis attribute="neither">At the final visit, the proportion of patients who had at least minimal improvement in their CGI-C ratings was significantly higher in the active-treatment groups compared with placebo (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.0001).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="positive"> Armodafinil demonstrated significant improvements compared with placebo in power of attention, quality of episodic secondary memory, and speed of memory (all </citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.05).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="neither"> Improvements were observed at the week 4 visit and were maintained throughout the 12-week study period.</citation_analysis></p>
        </sec>
        <sec>
          <title>Open-label studies</title>
          <p><citation_analysis attribute="neither">Two noncomparative open-label studies of armodafinil that focused primarily on patient-reported outcomes have also been completed. These studies enrolled 1071 patients with OSA, SWD, or narcolepsy. One study</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b71-nss-2-095">71</xref></citation_analysis><citation_analysis attribute="neither"> exclusively enrolled patients who had taken part in any of the aforementioned placebo-controlled, double-blind studies, while the other was also open to subjects who had not participated in the earlier trials.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b72-nss-2-095">72</xref></citation_analysis><citation_analysis attribute="neither"> Patients’ overall clinical condition was significantly improved with armodafinil compared with baseline values.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b71-nss-2-095">71</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b72-nss-2-095">72</xref></citation_analysis><citation_analysis attribute="neither"> At the final visit, between 75% and 98% of patients with OSA, narcolepsy, or SWD were deemed to have at least a minimal clinical improvement according to CGI-C ratings.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b71-nss-2-095">71</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b72-nss-2-095">72</xref></citation_analysis><citation_analysis attribute="neither"> Furthermore, 66% of armodafinil-treated patients with ES associated with OSA or narcolepsy perceived their clinical condition as “very much improved” or “much improved.”</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b73-nss-2-095">73</xref></citation_analysis></p>
        </sec>
      </sec>
      <sec sec-type="discussion">
        <title>Impact of armodafinil on patient-focused outcomes</title>
        <p><citation_analysis attribute="positive">As ES associated with sleep/wake disorders has such a serious impact on patients’ daily lives, it is important to assess armodafinil’s treatment effects from the patient’s perspective. Armodafinil has been studied with regard to a number of patient-focused aspects.</citation_analysis></p>
        <sec>
          <title>Subjective sleepiness</title>
          <p><citation_analysis attribute="positive">In clinical studies of armodafinil, ES has been measured subjectively using either the ESS or the Karolinska Sleepiness Scale (KSS). ESS scores in patients with treated OSA and residual ES showed that almost half (49%) of patients in the armodafinil group responded to treatment compared with one-quarter (26%) of patients in the placebo group.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="neither"> Use of the ESS also enabled investigators to establish that patients with ES associated with OSA treated with armodafinil experienced improvements in their ability to engage in activities of daily living at all study visits (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.0001).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="neither"> Furthermore, armodafinil significantly improved ESS scores compared with placebo in patients with OSA (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.01).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b74-nss-2-095">74</xref></citation_analysis></p>
          <p><citation_analysis attribute="negative">Armodafinil was effective in reducing subjective ES in patients with narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="neither"> At the final visit, 21%, 25%, and 7% of patients with narcolepsy who were given armodafinil 150 mg, armodafinil 250 mg, or placebo, respectively, had an ESS score indicative of normal alertness (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.05).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis></p>
          <p><citation_analysis attribute="neither">The KSS is particularly useful for assessing the intrusion of sleep into states of wakefulness.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b75-nss-2-095">75</xref></citation_analysis><citation_analysis attribute="positive"> Using the KSS, patients with SWD treated with armodafinil reported a significant reduction in ES at week 12 compared with those given placebo (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> ≤ 0.01).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis></p>
          <p><citation_analysis attribute="neither">Data derived from electronic diaries completed by patients with SWD revealed that armodafinil significantly reduced maximum ES during the night shift (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="positive"> &lt; 0.001 vs placebo) and demonstrated that armodafinil was associated with a twofold reduction in ES during the commute home (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.01 vs placebo).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="neither"> Electronic diaries used in a study of patients with narcolepsy revealed that armodafinil reduced the number of unintended daily sleep episodes by between 33% and 44% compared with 10% in the placebo group (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.0001).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="neither"> In addition, the mean number of daily naps were reduced by between 41% and 44% in the armodafinil-treated group compared with 22% in patients who received placebo (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.01).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis></p>
        </sec>
        <sec>
          <title>Fatigue</title>
          <p><citation_analysis attribute="positive">In a study of patients with OSA-associated ES with or without depression, a significant reduction in fatigue (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="positive"> &lt; 0.01) was reported by armodafinil-treated patients vs the placebo group when assessed using the Brief Fatigue Inventory (BFI).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b76-nss-2-095">76</xref></citation_analysis><citation_analysis attribute="positive"> Patients with narcolepsy have also reported significantly better relief from the fatigue associated with ES (</citation_analysis><citation_analysis attribute="positive"><italic>P</italic></citation_analysis><citation_analysis attribute="neither"> &lt; 0.001) when treated with armodafinil vs placebo.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="positive"> In an open-label extension study of patients with OSA, SWD, or narcolepsy, armodafinil was associated with an overall improvement from baseline in fatigue and a reduction in worst fatigue, as measured using the BFI.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b71-nss-2-095">71</xref></citation_analysis></p>
        </sec>
        <sec>
          <title>Quality of life</title>
          <p><citation_analysis attribute="positive">Although data on the impact of armodafinil on patients’ QOL have not been explicitly reported, 71% of patients who were administered armodafinil in a recent open-label study reported an improved ability to engage in daily activities.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b73-nss-2-095">73</xref></citation_analysis><citation_analysis attribute="positive"> The improvements seen in patient-reported outcomes, including subjective ES, cognitive function, and fatigue, are likely to have a positive impact on patients’ lives and well-being.</citation_analysis></p>
        </sec>
      </sec>
      <sec>
        <title>Safety and tolerability of armodafinil</title>
        <p><citation_analysis attribute="neither">Armodafinil was generally well tolerated in randomized trials and open-label extension studies of patients with OSA, SWD, or narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b71-nss-2-095">71</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b72-nss-2-095">72</xref></citation_analysis><citation_analysis attribute="positive"> Adverse events were reported to be mild to moderate in intensity, with the most common events being headache, nasopharyngitis, anxiety, and insomnia.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b71-nss-2-095">71</xref></citation_analysis><citation_analysis attribute="neither"> In the randomized studies of patients with OSA, narcolepsy, and SWD, headache occurred in 17%, 22%, and 12% of these patients, respectively (</citation_analysis><citation_analysis attribute="positive"><xref ref-type="table" rid="t3-nss-2-095">Table 3</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis><citation_analysis attribute="neither"> In the two open-label studies, headache occurred in 17%</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b72-nss-2-095">72</xref></citation_analysis><citation_analysis attribute="neither"> and 25%</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b71-nss-2-095">71</xref></citation_analysis><citation_analysis attribute="positive"> of patients. Overall, no clinically meaningful changes in mean laboratory variables, vital sign measurements, electrocardiogram, or physical examination findings were reported for patients treated with armodafinil.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b72-nss-2-095">72</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">Patient compliance with armodafinil therapy was good, with similar discontinuation rates to those reported with placebo.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b77-nss-2-095">77</xref></citation_analysis><citation_analysis attribute="neither"> Of the patients treated with armodafinil in the randomized trials, less than 12% in any study withdrew from study treatment because of an emergent adverse event. Approximately 6% of patients who received placebo in these studies withdrew due to adverse events.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b38-nss-2-095">38</xref></citation_analysis><citation_analysis attribute="neither">–</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis></p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p><citation_analysis attribute="negative">The personal, social, and economic implications of ES associated with OSA, SWD, or narcolepsy are immense, putting individuals at increased risk for serious health problems, work-related accidents, and road traffic crashes. Treating the underlying cause of ES in patients is vital in order to address this potentially serious issue. However, pharmacotherapy may be required in patients who experience residual ES despite adequate therapy for OSA and in those who have narcolepsy-related ES. Furthermore, some patients who experience ES as a symptom of SWD may not be able to alter their work schedule and may not find their condition abates with behavioral treatments; such patients may, therefore, also require medication to remain wakeful.</citation_analysis></p>
      <p><citation_analysis attribute="positive">The clinical trial results reported herein indicate that armodafinil produces statistically and clinically significant reductions in ES in patients with OSA, SWD, and narcolepsy. For example, a mean sleep latency of ≤5 minutes, as measured using the MSLT, is considered pathological. In the study by Czeisler et al,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="positive"> enrolled patients with SWD had a mean sleep latency of 2.3–2.4 minutes at baseline, which was improved to &gt;5 minutes (above the cutoff for pathological sleepiness) at the final visit in patients given armodafinil. This &gt;3-minute increase in sleep latency indicates that the biologic sleep drive of these patients has diminished and that their general functionality has improved. In addition, findings from these randomized and open-label clinical studies show armodafinil to be well tolerated with mild to moderate adverse events. Armodafinil may also improve memory and attention in patients with ES.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="positive"> Moreover, the wakefulness-promoting effects of armodafinil are of a similar magnitude to those of modafinil. However, the effects of armodafinil may persist for longer than those of modafinil,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b70-nss-2-095">70</xref></citation_analysis><citation_analysis attribute="neither"> indicating that armodafinil is a useful option for patients who may wish to remain alert later in the day.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Studies of the effect of armodafinil on ES in other patient groups are ongoing or planned and include patients with mild or moderate closed traumatic brain injury (NCT00893789) and patients with sarcoidosis (NCT00555347). Armodafinil is also being investigated as a treatment for jet lag and initial results have been favorable in this indication.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b78-nss-2-095">78</xref></citation_analysis><citation_analysis attribute="neither"> Further studies of armodafinil may expand its clinical value; however, more safety and efficacy studies are required before armodafinil can be recommended for promoting wakefulness in a wider context, such as instances where public safety or welfare may be an issue. Additional research to elucidate how armodafinil (and modafinil) promote wakefulness would be beneficial, as the mechanisms of action of these agents remain poorly understood at this time.</citation_analysis></p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p><citation_analysis attribute="neither">Editorial support was provided by Jane Bryant of Anthemis Consulting Ltd and was funded by Cephalon Inc, Frazer, PA, who provided a medical accuracy review. The authors were not compensated and retained full editorial control over the content of the paper.</citation_analysis></p>
    </ack>
    <fn-group>
      <fn>
        <p><citation_analysis attribute="positive">
          </citation_analysis><citation_analysis attribute="positive"><bold>Disclosures</bold></citation_analysis><citation_analysis attribute="positive">
        </citation_analysis></p>
        <p><citation_analysis attribute="neither">Dr Rosenberg has received research funding from Cephalon Inc, Pfizer Inc, sanofi-aventis, Respironics, Neurogen, Vanda Pharmaceuticals, Merck, and GlaxoSmithKline.</citation_analysis></p>
        <p><citation_analysis attribute="neither">Dr Bogan is a shareholder and employee of SleepMed Inc.; acts as a consultant to Cephalon Inc., GlaxoSmithKline, and Jazz Pharmaceuticals; has conducted industry-funded research for Actelion Pharmaceuticals Ltd, Addrenex Pharmaceuticals Inc., Apnicure Inc., Arena Pharmaceuticals Inc., Boehringer Ingelheim, Cephalon Inc., Evotec, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson and Johnson, Eli Lilly and Co., Merck &amp; Co. Inc., Neurogen Corporation, Novartis, Philips, Pfizer Inc., ResMed, sanofi-aventis, Schwarz Pharma, Sensory Medical Inc., Sepracor Inc., Vanda Pharmaceuticals Inc., Ventus Medical, and XenoPort Inc.; and has taken part in speaker bureau engagements for Cephalon Inc., Jazz Pharmaceuticals sanofi-aventis, and Sepracor Inc.</citation_analysis></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="b1-nss-2-095">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sack</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Auckley</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Auger</surname>
              <given-names>RR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review</article-title>
          <source>Sleep</source>
          <year>2007</year>
          <volume>30</volume>
          <issue>11</issue>
          <fpage>1460</fpage>
          <lpage>1483</lpage>
          <pub-id pub-id-type="pmid">18041480</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-nss-2-095">
        <label>2</label>
        <element-citation publication-type="book">
          <collab>National Sleep Foundation</collab>
          <source>2008 Sleep in America Poll</source>
          <publisher-loc>Washington DC</publisher-loc>
          <publisher-name>National Sleep Foundation</publisher-name>
          <year>2008</year>
        </element-citation>
      </ref>
      <ref id="b3-nss-2-095">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thorpy</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Lieberman</surname>
              <given-names>JA</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Owens</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Patient identification</article-title>
          <source>Am J Manag Care</source>
          <year>2007</year>
          <volume>13</volume>
          <issue>Suppl 6</issue>
          <fpage>S132</fpage>
          <lpage>S139</lpage>
          <pub-id pub-id-type="pmid">18041874</pub-id>
        </element-citation>
      </ref>
      <ref id="b4-nss-2-095">
        <label>4</label>
        <element-citation publication-type="journal">
          <collab>National Heart, Lung, and Blood Institute Working Group on Insomnia</collab>
          <article-title>Insomnia: assessment and management in primary care</article-title>
          <source>Am Fam Physician</source>
          <year>1999</year>
          <volume>59</volume>
          <issue>11</issue>
          <fpage>3029</fpage>
          <lpage>3038</lpage>
          <pub-id pub-id-type="pmid">10392587</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-nss-2-095">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neubauer</surname>
              <given-names>DN</given-names>
            </name>
          </person-group>
          <article-title>Current and new thinking in the management of comorbid insomnia</article-title>
          <source>Am J Manag Care</source>
          <year>2009</year>
          <volume>15</volume>
          <issue>Suppl</issue>
          <fpage>S24</fpage>
          <lpage>S32</lpage>
          <pub-id pub-id-type="pmid">19298103</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-nss-2-095">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sateia</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Update on sleep and psychiatric disorders</article-title>
          <source>Chest</source>
          <year>2009</year>
          <volume>135</volume>
          <issue>5</issue>
          <fpage>1370</fpage>
          <lpage>1379</lpage>
          <pub-id pub-id-type="pmid">19420207</pub-id>
        </element-citation>
      </ref>
      <ref id="b7-nss-2-095">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parish</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Sleep-related problems in common medical conditions</article-title>
          <source>Chest</source>
          <year>2009</year>
          <volume>135</volume>
          <issue>2</issue>
          <fpage>563</fpage>
          <lpage>572</lpage>
          <pub-id pub-id-type="pmid">19201722</pub-id>
        </element-citation>
      </ref>
      <ref id="b8-nss-2-095">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pilcher</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Ginter</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Sadowsky</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Sleep quality versus sleep quantity: relationships between sleep and measures of health, well-being and sleepiness in college students</article-title>
          <source>J Psychosom Res</source>
          <year>1997</year>
          <volume>42</volume>
          <issue>6</issue>
          <fpage>583</fpage>
          <lpage>596</lpage>
          <pub-id pub-id-type="pmid">9226606</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-nss-2-095">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Newman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Spiekerman</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Enright</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Daytime sleepiness predicts mortality and cardiovascular disease in older adults. The Cardiovascular Health Study Research Group</article-title>
          <source>J Am Geriatr Soc</source>
          <year>2000</year>
          <volume>48</volume>
          <issue>2</issue>
          <fpage>115</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="pmid">10682939</pub-id>
        </element-citation>
      </ref>
      <ref id="b10-nss-2-095">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elwood</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hack</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pickering</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gallacher</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort</article-title>
          <source>J Epidemiol Community Health</source>
          <year>2006</year>
          <volume>60</volume>
          <issue>1</issue>
          <fpage>69</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">16361457</pub-id>
        </element-citation>
      </ref>
      <ref id="b11-nss-2-095">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bixler</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Vigontzas</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Calhoun</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Vela-Bueno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kales</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2005</year>
          <volume>90</volume>
          <issue>8</issue>
          <fpage>4510</fpage>
          <lpage>4515</lpage>
          <pub-id pub-id-type="pmid">15941867</pub-id>
        </element-citation>
      </ref>
      <ref id="b12-nss-2-095">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferini-Strambi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Baietto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Di Giola</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cognitive dysfunction in patients with obstructive sleep apnea (OSA): partial reversibility after positive airway pressure (CPAP)</article-title>
          <source>Brain Res Bull</source>
          <year>2003</year>
          <volume>61</volume>
          <issue>1</issue>
          <fpage>87</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">12788211</pub-id>
        </element-citation>
      </ref>
      <ref id="b13-nss-2-095">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dean</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aguilar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impaired health status, daily functioning, and work productivity in adults with excessive sleepiness</article-title>
          <source>J Occup Environ Med</source>
          <year>2010</year>
          <volume>52</volume>
          <fpage>144</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="pmid">20134351</pub-id>
        </element-citation>
      </ref>
      <ref id="b14-nss-2-095">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Omachi</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Claman</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Blanc</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Eisner</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Obstructive sleep apnea: a risk factor for work disability</article-title>
          <source>Sleep</source>
          <year>2009</year>
          <volume>32</volume>
          <issue>6</issue>
          <fpage>791</fpage>
          <lpage>798</lpage>
          <pub-id pub-id-type="pmid">19544756</pub-id>
        </element-citation>
      </ref>
      <ref id="b15-nss-2-095">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drake</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Roehrs</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers</article-title>
          <source>Sleep</source>
          <year>2004</year>
          <volume>27</volume>
          <issue>8</issue>
          <fpage>1453</fpage>
          <lpage>1462</lpage>
          <pub-id pub-id-type="pmid">15683134</pub-id>
        </element-citation>
      </ref>
      <ref id="b16-nss-2-095">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leger</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research</article-title>
          <source>Sleep</source>
          <year>1994</year>
          <volume>17</volume>
          <issue>1</issue>
          <fpage>84</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">7677805</pub-id>
        </element-citation>
      </ref>
      <ref id="b17-nss-2-095">
        <label>17</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Flatley</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Reyner</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Horne</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <source>Sleep-related crashes on sections of different road types in the UK (1995–2001)</source>
          <publisher-loc>London</publisher-loc>
          <publisher-name>Department of Transport, Road Safety Research</publisher-name>
          <comment>Report No 52</comment>
          <year>2004</year>
        </element-citation>
      </ref>
      <ref id="b18-nss-2-095">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pandi-Perumal</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Verster</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Kayumov</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sleep disorders, sleepiness and traffic safety: a public health menace</article-title>
          <source>Braz J Med Biol Res</source>
          <year>2006</year>
          <volume>39</volume>
          <issue>7</issue>
          <fpage>863</fpage>
          <lpage>871</lpage>
          <pub-id pub-id-type="pmid">16862276</pub-id>
        </element-citation>
      </ref>
      <ref id="b19-nss-2-095">
        <label>19</label>
        <mixed-citation publication-type="webpage"><collab>US Department of Transportation</collab><source>Effects of sleep schedules on commercial motor vehicle driver performance</source><year>2000</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.fmcsa.dot.gov/documents/execsumm-e1.pdf">http://www.fmcsa.dot.gov/documents/execsumm-e1.pdf</ext-link></comment>Accessed <date-in-citation>Dec 22, 2009</date-in-citation></mixed-citation>
      </ref>
      <ref id="b20-nss-2-095">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopes</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Esteves</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Bittencourt</surname>
              <given-names>LRA</given-names>
            </name>
            <name>
              <surname>Tufik</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mello</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Relationship between the quality of life and the severity of obstructive sleep apnea syndrome</article-title>
          <source>Braz J Med Biol Res</source>
          <year>2008</year>
          <volume>41</volume>
          <issue>10</issue>
          <fpage>908</fpage>
          <lpage>913</lpage>
          <pub-id pub-id-type="pmid">18820762</pub-id>
        </element-citation>
      </ref>
      <ref id="b21-nss-2-095">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dodel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Noelker</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Health-related quality of life in patients with narcolepsy</article-title>
          <source>Sleep Med</source>
          <year>2007</year>
          <volume>8</volume>
          <issue>7–8</issue>
          <fpage>733</fpage>
          <lpage>741</lpage>
          <pub-id pub-id-type="pmid">17512797</pub-id>
        </element-citation>
      </ref>
      <ref id="b22-nss-2-095">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Health-related quality of life among drug-naïve patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time</article-title>
          <source>J Clin Sleep Med</source>
          <year>2008</year>
          <volume>4</volume>
          <issue>6</issue>
          <fpage>572</fpage>
          <lpage>578</lpage>
          <pub-id pub-id-type="pmid">19110887</pub-id>
        </element-citation>
      </ref>
      <ref id="b23-nss-2-095">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baldwin</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Griffth</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Nieto</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>O’Connor</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Wasleben</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Redline</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The association of sleep-disordered breathing and sleep symptoms with quality of life in the Sleep Heart Health Study</article-title>
          <source>Sleep</source>
          <year>2001</year>
          <volume>24</volume>
          <fpage>96</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="pmid">11204058</pub-id>
        </element-citation>
      </ref>
      <ref id="b24-nss-2-095">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Briones</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Strauss</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Relationship between sleepiness and general health status</article-title>
          <source>Sleep</source>
          <year>1996</year>
          <volume>19</volume>
          <fpage>583</fpage>
          <lpage>588</lpage>
          <pub-id pub-id-type="pmid">8899938</pub-id>
        </element-citation>
      </ref>
      <ref id="b25-nss-2-095">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reimer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Flemons</surname>
              <given-names>W W</given-names>
            </name>
          </person-group>
          <article-title>Quality of life in sleep disorders</article-title>
          <source>Sleep Med Rev</source>
          <year>2003</year>
          <volume>7</volume>
          <fpage>335</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="pmid">14505600</pub-id>
        </element-citation>
      </ref>
      <ref id="b26-nss-2-095">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sforza</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Janssens</surname>
              <given-names>J P</given-names>
            </name>
            <name>
              <surname>Rochat</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ibanez</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Determinants of quality of life in patients with sleep-related breathing disorders</article-title>
          <source>Eur Respir J</source>
          <year>2003</year>
          <volume>21</volume>
          <issue>4</issue>
          <fpage>682</fpage>
          <lpage>687</lpage>
          <pub-id pub-id-type="pmid">12762357</pub-id>
        </element-citation>
      </ref>
      <ref id="b27-nss-2-095">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chervin</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea</article-title>
          <source>Chest</source>
          <year>2000</year>
          <volume>118</volume>
          <issue>2</issue>
          <fpage>372</fpage>
          <lpage>379</lpage>
          <pub-id pub-id-type="pmid">10936127</pub-id>
        </element-citation>
      </ref>
      <ref id="b28-nss-2-095">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johns</surname>
              <given-names>M W</given-names>
            </name>
          </person-group>
          <article-title>A new method for measuring daytime sleepiness: the Epworth sleepiness scale</article-title>
          <source>Sleep</source>
          <year>1991</year>
          <volume>14</volume>
          <issue>6</issue>
          <fpage>540</fpage>
          <lpage>545</lpage>
          <pub-id pub-id-type="pmid">1798888</pub-id>
        </element-citation>
      </ref>
      <ref id="b29-nss-2-095">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carskadon</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Dement</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Mitler</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Westbrook</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Keenan</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness</article-title>
          <source>Sleep</source>
          <year>1986</year>
          <volume>9</volume>
          <fpage>519</fpage>
          <lpage>524</lpage>
          <pub-id pub-id-type="pmid">3809866</pub-id>
        </element-citation>
      </ref>
      <ref id="b30-nss-2-095">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Littner</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Kushida</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wise</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test</article-title>
          <source>Sleep</source>
          <year>2005</year>
          <volume>28</volume>
          <fpage>113</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="pmid">15700727</pub-id>
        </element-citation>
      </ref>
      <ref id="b31-nss-2-095">
        <label>31</label>
        <element-citation publication-type="book">
          <collab>American Academy of Sleep Medicine</collab>
          <article-title>International Classification of Sleep Disorders</article-title>
          <source>Diagnostic and Coding Manual</source>
          <edition>2nd Ed.</edition>
          <publisher-loc>Westchester, IL</publisher-loc>
          <publisher-name>American Academy of Sleep Medicine</publisher-name>
          <year>2005</year>
        </element-citation>
      </ref>
      <ref id="b32-nss-2-095">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Young</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Palta</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dempsey</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Skatrud</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Badr</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The occurrence of sleep-disordered breathing among middle-aged adults</article-title>
          <source>N Engl J Med</source>
          <year>1993</year>
          <volume>328</volume>
          <issue>17</issue>
          <fpage>1230</fpage>
          <lpage>1235</lpage>
          <pub-id pub-id-type="pmid">8464434</pub-id>
        </element-citation>
      </ref>
      <ref id="b33-nss-2-095">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>IE</given-names></name><name><surname>Quinnell</surname><given-names>TG</given-names></name></person-group><article-title>Pharmacotherapies for obstructive sleep apnoea: where are we now</article-title>? <source>Drugs</source><year>2004</year><volume>64</volume><issue>13</issue><fpage>1385</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">15212557</pub-id></mixed-citation>
      </ref>
      <ref id="b34-nss-2-095">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sullivan</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Issa</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Berthon-Jones</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eves</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares</article-title>
          <source>Lancet</source>
          <year>1981</year>
          <volume>1</volume>
          <issue>8225</issue>
          <fpage>862</fpage>
          <lpage>865</lpage>
          <pub-id pub-id-type="pmid">6112294</pub-id>
        </element-citation>
      </ref>
      <ref id="b35-nss-2-095">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weaver</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Maislin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dinges</surname>
              <given-names>DF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning</article-title>
          <source>Sleep</source>
          <year>2007</year>
          <volume>30</volume>
          <issue>6</issue>
          <fpage>711</fpage>
          <lpage>719</lpage>
          <pub-id pub-id-type="pmid">17580592</pub-id>
        </element-citation>
      </ref>
      <ref id="b36-nss-2-095">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morgenthaler</surname>
              <given-names>TI</given-names>
            </name>
            <name>
              <surname>Kapen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lee-Chiong</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Practice parameters for the medical therapy of obstructive sleep apnea</article-title>
          <source>Sleep</source>
          <year>2006</year>
          <volume>29</volume>
          <issue>8</issue>
          <fpage>1031</fpage>
          <lpage>1035</lpage>
          <pub-id pub-id-type="pmid">16944671</pub-id>
        </element-citation>
      </ref>
      <ref id="b37-nss-2-095">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Black</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Hirshkowitz</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome</article-title>
          <source>Sleep</source>
          <year>2005</year>
          <volume>28</volume>
          <issue>4</issue>
          <fpage>464</fpage>
          <lpage>471</lpage>
          <pub-id pub-id-type="pmid">16171291</pub-id>
        </element-citation>
      </ref>
      <ref id="b38-nss-2-095">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirshkowitz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Wesnes</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Niebler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Arora</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome</article-title>
          <source>Respir Med</source>
          <year>2007</year>
          <volume>101</volume>
          <issue>3</issue>
          <fpage>616</fpage>
          <lpage>627</lpage>
          <pub-id pub-id-type="pmid">16908126</pub-id>
        </element-citation>
      </ref>
      <ref id="b39-nss-2-095">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schmidt-Nowara</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults</article-title>
          <source>Clin Ther</source>
          <year>2006</year>
          <volume>28</volume>
          <issue>5</issue>
          <fpage>689</fpage>
          <lpage>706</lpage>
          <pub-id pub-id-type="pmid">16861091</pub-id>
        </element-citation>
      </ref>
      <ref id="b40-nss-2-095">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rippon</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Arora</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea</article-title>
          <source>Sleep Breath</source>
          <year>2008</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>53</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">17874255</pub-id>
        </element-citation>
      </ref>
      <ref id="b41-nss-2-095">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Hirshkowitz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Erman</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Schmidt-Nowara</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week open-label study</article-title>
          <source>Chest</source>
          <year>2003</year>
          <volume>124</volume>
          <issue>6</issue>
          <fpage>2192</fpage>
          <lpage>2199</lpage>
          <pub-id pub-id-type="pmid">14665500</pub-id>
        </element-citation>
      </ref>
      <ref id="b42-nss-2-095">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Shift work sleep disorder: burden of illness and approaches to management</article-title>
          <source>Drugs</source>
          <year>2006</year>
          <volume>66</volume>
          <issue>18</issue>
          <fpage>2357</fpage>
          <lpage>2370</lpage>
          <pub-id pub-id-type="pmid">17181377</pub-id>
        </element-citation>
      </ref>
      <ref id="b43-nss-2-095">
        <label>43</label>
        <mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>McMenamin</surname><given-names>TM</given-names></name></person-group><article-title>A time to work: recent trends in shift work and fexible schedules</article-title><source>Month Lab Rev</source>Dec 2007:<fpage>3</fpage><lpage>15</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.bls.gov/opub/mlr/2007/12/art1full.pdf">http://www.bls.gov/opub/mlr/2007/12/art1full.pdf</ext-link></comment>Accessed <date-in-citation>Oct 15, 2009</date-in-citation></mixed-citation>
      </ref>
      <ref id="b44-nss-2-095">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waage</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moen</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Pallesen</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Shift work disorder among oil rig workers in the North Sea</article-title>
          <source>Sleep</source>
          <year>2009</year>
          <volume>32</volume>
          <issue>4</issue>
          <fpage>558</fpage>
          <lpage>565</lpage>
          <pub-id pub-id-type="pmid">19413151</pub-id>
        </element-citation>
      </ref>
      <ref id="b45-nss-2-095">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Czeisler</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Modafinil for excessive sleepiness associated with shift-work disorder</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <issue>5</issue>
          <fpage>476</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="pmid">16079371</pub-id>
        </element-citation>
      </ref>
      <ref id="b46-nss-2-095">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Czeisler</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Wesnes</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Arora</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study</article-title>
          <source>Mayo Clin Proc</source>
          <year>2009</year>
          <volume>84</volume>
          <issue>11</issue>
          <fpage>958</fpage>
          <lpage>972</lpage>
          <pub-id pub-id-type="pmid">19880686</pub-id>
        </element-citation>
      </ref>
      <ref id="b47-nss-2-095">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erman</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>R</given-names>
            </name>
            <collab>for the US Modafinil Shift Work Sleep Disorder Study Group</collab>
          </person-group>
          <article-title>Modafinil for excessive sleepiness associated with chronic shift-work sleep disorder: effects on patient functioning and health-related quality of life</article-title>
          <source>Prim Care Companion J Clin Psychiatry</source>
          <year>2007</year>
          <volume>9</volume>
          <issue>3</issue>
          <fpage>188</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="pmid">17632651</pub-id>
        </element-citation>
      </ref>
      <ref id="b48-nss-2-095">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hart</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Haney</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nasser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Foltin</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>Combined effects of methamphetamine and zolpidem on performance and mood during simulated night shift work</article-title>
          <source>Pharmacol Biochem Behav</source>
          <year>2005</year>
          <volume>81</volume>
          <issue>3</issue>
          <fpage>559</fpage>
          <lpage>568</lpage>
          <pub-id pub-id-type="pmid">15936062</pub-id>
        </element-citation>
      </ref>
      <ref id="b49-nss-2-095">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Longstreth</surname>
              <given-names>WT</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Ton</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Koepsell</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gersuk</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Hendrickson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Velde</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Prevalence of narcolepsy in King County, Washington, USA</article-title>
          <source>Sleep Med</source>
          <year>2009</year>
          <volume>10</volume>
          <issue>4</issue>
          <fpage>422</fpage>
          <lpage>426</lpage>
          <pub-id pub-id-type="pmid">19013100</pub-id>
        </element-citation>
      </ref>
      <ref id="b50-nss-2-095">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wise</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Arand</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Auger</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Brooks</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>NF</given-names>
            </name>
            <collab>for the American Academy of Sleep Medicine</collab>
          </person-group>
          <article-title>Treatment of narcolepsy and other hypersomnias of central origin</article-title>
          <source>Sleep</source>
          <year>2007</year>
          <volume>30</volume>
          <issue>12</issue>
          <fpage>1712</fpage>
          <lpage>1727</lpage>
          <pub-id pub-id-type="pmid">18246981</pub-id>
        </element-citation>
      </ref>
      <ref id="b51-nss-2-095">
        <label>51</label>
        <element-citation publication-type="journal">
          <collab>US Xyrem Multicenter Study Group</collab>
          <article-title>A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy</article-title>
          <source>Sleep</source>
          <year>2002</year>
          <volume>25</volume>
          <issue>1</issue>
          <fpage>42</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">11833860</pub-id>
        </element-citation>
      </ref>
      <ref id="b52-nss-2-095">
        <label>52</label>
        <element-citation publication-type="journal">
          <collab>US Xyrem Multicenter Study Group</collab>
          <article-title>Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy</article-title>
          <source>Sleep Med</source>
          <year>2004</year>
          <volume>5</volume>
          <issue>2</issue>
          <fpage>119</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="pmid">15033130</pub-id>
        </element-citation>
      </ref>
      <ref id="b53-nss-2-095">
        <label>53</label>
        <element-citation publication-type="journal">
          <collab>Xyrem International Study Group</collab>
          <article-title>A double-blind placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy</article-title>
          <source>J Clin Sleep Med</source>
          <year>2005</year>
          <volume>1</volume>
          <issue>4</issue>
          <fpage>391</fpage>
          <lpage>397</lpage>
          <pub-id pub-id-type="pmid">17564408</pub-id>
        </element-citation>
      </ref>
      <ref id="b54-nss-2-095">
        <label>54</label>
        <element-citation publication-type="journal">
          <collab>Xyrem International Study Group</collab>
          <article-title>Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients</article-title>
          <source>Sleep Med</source>
          <year>2005</year>
          <volume>6</volume>
          <issue>5</issue>
          <fpage>415</fpage>
          <lpage>421</lpage>
          <pub-id pub-id-type="pmid">16099718</pub-id>
        </element-citation>
      </ref>
      <ref id="b55-nss-2-095">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harsh</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Haydak</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy</article-title>
          <source>Curr Med Res Opin</source>
          <year>2006</year>
          <volume>22</volume>
          <issue>4</issue>
          <fpage>761</fpage>
          <lpage>774</lpage>
          <pub-id pub-id-type="pmid">16684437</pub-id>
        </element-citation>
      </ref>
      <ref id="b56-nss-2-095">
        <label>56</label>
        <element-citation publication-type="journal">
          <collab>US Modafinil in Narcolepsy Multicenter Study Group</collab>
          <article-title>Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy</article-title>
          <source>Ann Neurol</source>
          <year>1998</year>
          <volume>43</volume>
          <issue>1</issue>
          <fpage>88</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="pmid">9450772</pub-id>
        </element-citation>
      </ref>
      <ref id="b57-nss-2-095">
        <label>57</label>
        <element-citation publication-type="journal">
          <collab>US Modafinil in Narcolepsy Multicenter Study Group</collab>
          <article-title>Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy</article-title>
          <source>Neurology</source>
          <year>2000</year>
          <volume>54</volume>
          <issue>5</issue>
          <fpage>1166</fpage>
          <lpage>1175</lpage>
          <pub-id pub-id-type="pmid">10720292</pub-id>
        </element-citation>
      </ref>
      <ref id="b58-nss-2-095">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>YN</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>S P</given-names>
            </name>
            <name>
              <surname>Simcoe</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects</article-title>
          <source>J Clin Pharmacol</source>
          <year>1999</year>
          <volume>39</volume>
          <issue>3</issue>
          <fpage>281</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="pmid">10073328</pub-id>
        </element-citation>
      </ref>
      <ref id="b59-nss-2-095">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>YN</given-names>
            </name>
            <name>
              <surname>Simcoe</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hartman</surname>
              <given-names>LN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers</article-title>
          <source>J Clin Pharmacol</source>
          <year>1999</year>
          <volume>39</volume>
          <issue>1</issue>
          <fpage>30</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">9987698</pub-id>
        </element-citation>
      </ref>
      <ref id="b60-nss-2-095">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferraro</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fuxe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tanganelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tomasini</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Rambert</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Antonelli</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Differential enhancement of dialysate serotonin levels in distinct brain regions of the rat by modafinil: possible relevance for wakefulness and depression</article-title>
          <source>J Neurosci Res</source>
          <year>2002</year>
          <volume>68</volume>
          <issue>1</issue>
          <fpage>107</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="pmid">11933055</pub-id>
        </element-citation>
      </ref>
      <ref id="b61-nss-2-095">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mitchell</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Bogenpohl</surname>
              <given-names>J W</given-names>
            </name>
            <name>
              <surname>Liles</surname>
              <given-names>LC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic – dopaminergic mechanism of action</article-title>
          <source>Pharmacol Biochem Behav</source>
          <year>2008</year>
          <volume>91</volume>
          <issue>2</issue>
          <fpage>217</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="pmid">18703079</pub-id>
        </element-citation>
      </ref>
      <ref id="b62-nss-2-095">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qu</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>ZL</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Urade</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Dopaminergic D<sub>1</sub> and D<sub>2</sub> receptors are essential for the arousal effect of modafinil</article-title>
          <source>J Neurosci</source>
          <year>2008</year>
          <volume>28</volume>
          <issue>34</issue>
          <fpage>8462</fpage>
          <lpage>8469</lpage>
          <pub-id pub-id-type="pmid">18716204</pub-id>
        </element-citation>
      </ref>
      <ref id="b63-nss-2-095">
        <label>63</label>
        <mixed-citation publication-type="webpage"><collab>Food and Drug Administration</collab><source>FDA-approved Labeling Text for NDA 21-875/NUVIGIL™ (armodafinil) Tablets</source><year>2007</year> June 15<comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf</ext-link></comment>Accessed <date-in-citation>Oct 15, 2009</date-in-citation></mixed-citation>
      </ref>
      <ref id="b64-nss-2-095">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z W</given-names>
            </name>
            <name>
              <surname>Borok</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prolonged wakefulness induces experience-dependent synaptic plasticity in mouse hypocretin/orexin neurons</article-title>
          <source>J Clin Invest</source>
          <year>2007</year>
          <volume>117</volume>
          <issue>12</issue>
          <fpage>4022</fpage>
          <lpage>4033</lpage>
          <pub-id pub-id-type="pmid">18060037</pub-id>
        </element-citation>
      </ref>
      <ref id="b65-nss-2-095">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beck</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Odle</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wallace-Huitt</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Skinner</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Garcia-Rill</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists</article-title>
          <source>Sleep</source>
          <year>2008</year>
          <volume>31</volume>
          <issue>12</issue>
          <fpage>1647</fpage>
          <lpage>1654</lpage>
          <pub-id pub-id-type="pmid">19090320</pub-id>
        </element-citation>
      </ref>
      <ref id="b66-nss-2-095">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Darwish</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kirby</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hellriegel</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>P</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half lives: analysis of data from three randomized, single-dose, pharmacokinetic studies</article-title>
          <source>Clin Drug Investig</source>
          <year>2009</year>
          <volume>29</volume>
          <issue>9</issue>
          <fpage>613</fpage>
          <lpage>623</lpage>
        </element-citation>
      </ref>
      <ref id="b67-nss-2-095">
        <label>67</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Darwish</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kirby</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hellriegel</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>P</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies</article-title>
          <source>Clin Drug Investig</source>
          <year>2009</year>
          <volume>29</volume>
          <issue>2</issue>
          <fpage>87</fpage>
          <lpage>100</lpage>
        </element-citation>
      </ref>
      <ref id="b68-nss-2-095">
        <label>68</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Darwish</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kirby</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>P</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Hellriegel</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
          <article-title>Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects</article-title>
          <source>Clin Pharmacokinet</source>
          <year>2008</year>
          <volume>47</volume>
          <issue>1</issue>
          <fpage>61</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">18076219</pub-id>
        </element-citation>
      </ref>
      <ref id="b69-nss-2-095">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wisor</surname>
              <given-names>J P</given-names>
            </name>
            <name>
              <surname>Dement</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Aimone</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bozyczko-Coyne</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Armodafinil, the <italic>R</italic>-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat</article-title>
          <source>Pharmacol Biochem Behav</source>
          <year>2006</year>
          <volume>85</volume>
          <issue>3</issue>
          <fpage>492</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="pmid">17134745</pub-id>
        </element-citation>
      </ref>
      <ref id="b70-nss-2-095">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dinges</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Arora</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Darwish</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Niebler</surname>
              <given-names>GE</given-names>
            </name>
          </person-group>
          <article-title>Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss</article-title>
          <source>Curr Med Res Opin</source>
          <year>2006</year>
          <volume>22</volume>
          <issue>1</issue>
          <fpage>159</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="pmid">16393442</pub-id>
        </element-citation>
      </ref>
      <ref id="b71-nss-2-095">
        <label>71</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Black</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hull</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Tiller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Harsh</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Maintenance of efficacy, safety and tolerability of armodafinil: an open-label extension study</article-title>
          <source>Sleep</source>
          <year>2009</year>
          <volume>32</volume>
          <issue>Suppl</issue>
          <fpage>A139</fpage>
          <comment>[Abstract No. 0419]</comment>
        </element-citation>
      </ref>
      <ref id="b72-nss-2-095">
        <label>72</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>McCall</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Weintraub</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tiller</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A 12-month or more open-label study of the efficacy and tolerability of armodafinil</article-title>
          <source>Sleep</source>
          <year>2009</year>
          <volume>32</volume>
          <issue>Suppl</issue>
          <fpage>A50</fpage>
          <lpage>A51</lpage>
          <comment>[Abstract No. 0148]</comment>
        </element-citation>
      </ref>
      <ref id="b73-nss-2-095">
        <label>73</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Tiller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bogan</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>Armodafinil improves patient-reported outcomes in patients with excessive sleepiness associated with obstructive sleep apnea or narcolepsy</article-title>
          <source>Sleep</source>
          <year>2009</year>
          <volume>32</volume>
          <issue>Suppl</issue>
          <fpage>A190</fpage>
          <comment>[Abstract No. 0580]</comment>
        </element-citation>
      </ref>
      <ref id="b74-nss-2-095">
        <label>74</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Krystal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Harsh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rippon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lankford</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>A randomised, double-blind, placebo-controlled study with armodafinil in patients with residual excessive sleepiness associated with CPAP-treated obstructive sleep apnoea and comorbid depressive disorders</source>
          <conf-name>Poster presented at the 19th Meeting of the European Neurological Society</conf-name>
          <conf-date>2009 June 20–24</conf-date>
          <conf-loc>Milan, Italy</conf-loc>
          <comment>[Abstract No. P353]</comment>
        </element-citation>
      </ref>
      <ref id="b75-nss-2-095">
        <label>75</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akerstedt</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gillberg</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Subjective and objective sleepiness in the active individual</article-title>
          <source>Int J Neurosci</source>
          <year>1990</year>
          <volume>52</volume>
          <issue>1–2</issue>
          <fpage>29</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">2265922</pub-id>
        </element-citation>
      </ref>
      <ref id="b76-nss-2-095">
        <label>76</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Hull</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lankford</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vince</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Niebler</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Arora</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <source>Armodafinil improves fatigue in patients with excessive sleepiness due to obstructive sleep apnea/hypopnea syndrome</source>
          <conf-name>Poster presented at the American Psychiatric Association Annual Meeting</conf-name>
          <conf-date>2006 May 25</conf-date>
          <conf-loc>Toronto, Canada</conf-loc>
          <comment>[Abstract No. 127]</comment>
        </element-citation>
      </ref>
      <ref id="b77-nss-2-095">
        <label>77</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Russo</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Pharmacotherapy of excessive sleepiness: focus on armodafinil</article-title>
          <source>Clin Med Ther</source>
          <year>2009</year>
          <volume>1</volume>
          <fpage>415</fpage>
          <lpage>432</lpage>
        </element-citation>
      </ref>
      <ref id="b78-nss-2-095">
        <label>78</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bogan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tiller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Youakim</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Armodafinil for excessive sleepiness associated with jet lag disorder</article-title>
          <source>Sleep</source>
          <year>2009</year>
          <volume>32</volume>
          <issue>Suppl</issue>
          <fpage>A52</fpage>
          <comment>[Abstract No. 0153]</comment>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-nss-2-095" position="float">
      <label>Figure 1</label>
      <caption>
        <p><citation_analysis attribute="neither">Structure of (</citation_analysis><citation_analysis attribute="positive"><bold>A</bold></citation_analysis><citation_analysis attribute="neither">) </citation_analysis><citation_analysis attribute="positive"><italic>R</italic></citation_analysis><citation_analysis attribute="neither">-modafinil and (</citation_analysis><citation_analysis attribute="positive"><bold>B</bold></citation_analysis><citation_analysis attribute="neither">) </citation_analysis><citation_analysis attribute="positive"><italic>S-</italic></citation_analysis><citation_analysis attribute="neither">modafinil. Armodafinil comprises only </citation_analysis><citation_analysis attribute="positive"><italic>R</italic></citation_analysis><citation_analysis attribute="neither">-modafinil, while racemic modafinil comprises a mixture of both </citation_analysis><citation_analysis attribute="positive"><italic>R</italic></citation_analysis><citation_analysis attribute="neither">- and </citation_analysis><citation_analysis attribute="positive"><italic>S-</italic></citation_analysis><citation_analysis attribute="neither">modafinil.</citation_analysis></p>
      </caption>
      <graphic xlink:href="nss-2-095Fig1"/>
    </fig>
    <table-wrap id="t1-nss-2-095" position="float">
      <label>Table 1</label>
      <caption>
        <p><citation_analysis attribute="neither">Pharmacokinetic parameters of armodafinil and modafinil</citation_analysis></p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">Parameters</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Armodafinil 200 mg (mean ± SD)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Modafinil 200 mg (mean ± SD)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub>(μg/mL)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">5.44 ± 1.64</td>
            <td align="left" valign="top" rowspan="1" colspan="1">4.61 ± 0.73</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>last</sub> (μg·h/mL)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">88.2 ± 29.6</td>
            <td align="left" valign="top" rowspan="1" colspan="1">66.5 ± 14.4</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>∞</sub> (μg·h/mL)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">95.8 ± 28.0</td>
            <td align="left" valign="top" rowspan="1" colspan="1">68.5 ± 15.3</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>t</italic><sub>max</sub> (h)<xref ref-type="table-fn" rid="tfn1-nss-2-095">a</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">1.8</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2.5</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>t</italic><sub>1/2</sub><sub>β</sub> (h)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">13.0 ± 2.6</td>
            <td align="left" valign="top" rowspan="1" colspan="1">13.6 ± 2.0</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><citation_analysis attribute="positive">
            </citation_analysis><citation_analysis attribute="positive"><bold>Note:</bold></citation_analysis><citation_analysis attribute="positive">
          </citation_analysis></p>
        </fn>
        <fn id="tfn1-nss-2-095">
          <label>a</label>
          <p><citation_analysis attribute="neither">Median values.</citation_analysis></p>
        </fn>
        <fn id="tfn2-nss-2-095">
          <p><citation_analysis attribute="neither">Reprinted with permission from Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug investig. 2009;29(9):613–623.</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b66-nss-2-095">66</xref></citation_analysis><citation_analysis attribute="neither"> Copyright </citation_analysis><citation_analysis attribute="positive"><bold>©</bold></citation_analysis><citation_analysis attribute="neither"> 2009 wolters Kluwer</citation_analysis></p>
        </fn>
        <fn id="tfn3-nss-2-095">
          <p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> AUC</citation_analysis><citation_analysis attribute="positive"><sub>last</sub></citation_analysis><citation_analysis attribute="neither">, area under the plasma drug concentration vs time curve from time zero to the time of the last measurable concentration; AUC</citation_analysis><citation_analysis attribute="positive"><sub>∞</sub></citation_analysis><citation_analysis attribute="neither">, area under the plasma drug concentration vs time curve from time zero to infinity; C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither">, maximum plasma drug concentration; SD, standard deviation; </citation_analysis><citation_analysis attribute="positive"><italic>t</italic></citation_analysis><citation_analysis attribute="positive"><sub>1/2</sub></citation_analysis><citation_analysis attribute="positive"><sub>β</sub></citation_analysis><citation_analysis attribute="neither">, terminal elimination half-life; </citation_analysis><citation_analysis attribute="positive"><italic>t</italic></citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither">, time to reach C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis></p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t2-nss-2-095" position="float">
      <label>Table 2</label>
      <caption>
        <p><citation_analysis attribute="positive">Wakefulness-promoting effects of armodafinil in the treatment of ES associated with OSA, SWD, and narcolepsy</citation_analysis></p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">Study/indication</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Patients (<italic>n</italic>)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Treatment</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Wakefulness</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="4" align="left" valign="top" rowspan="1">
              <bold>OSA</bold>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Hirshkowitz et al<xref ref-type="bibr" rid="b38-nss-2-095">38</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">259</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">MWT</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Armodafinil (150 mg/day)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">+2.3 min</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Placebo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">−1.3 min (<italic>P</italic> &lt; 0.001)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Roth et al<xref ref-type="bibr" rid="b39-nss-2-095">39</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">395</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">MWT</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Armodafinil (150/250 mg/day)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">+1.9 min</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Placebo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">−1.7 min (<italic>P</italic> &lt; 0.001)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Roth et al<xref ref-type="bibr" rid="b40-nss-2-095">40</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">658</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">MWT</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Armodafinil (150/250 mg/day)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">+2.0 min</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Placebo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">−1.5 min (<italic>P</italic> &lt; 0.0001)</td>
          </tr>
          <tr>
            <td colspan="4" align="left" valign="top" rowspan="1">
              <bold>SWD</bold>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Czeisler et al<xref ref-type="bibr" rid="b46-nss-2-095">46</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">245</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">MSLT</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Armodafinil (150 mg/day)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">+3.1 min</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Placebo (given 30–60 min before the shift)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">+0.4 min (<italic>P</italic> &lt; 0.001)</td>
          </tr>
          <tr>
            <td colspan="4" align="left" valign="top" rowspan="1">
              <bold>Narcolepsy</bold>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Harsh et al<xref ref-type="bibr" rid="b55-nss-2-095">55</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">194</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">MWT</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Armodafinil (150/250 mg/day)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">09:00–15:00: +1.9 min</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">15:00–19:00: +1.6 min</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">Placebo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">09:00–15:00: −1.9 min (<italic>P</italic> &lt; 0.01 vs armodafinil combined)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">15:00–19:00: −1.2 min (<italic>P</italic> &lt; 0.05 vs armodafinil combined)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn4-nss-2-095">
          <p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> ES, excessive sleepiness; MSLT, Multiple Sleep Latency Test; MWT, Maintenance of wakefulness Test; OSA, obstructive sleep apnea; SWD, shift-work disorder.</citation_analysis></p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t3-nss-2-095" position="float">
      <label>Table 3</label>
      <caption>
        <p><citation_analysis attribute="positive">The most commonly reported adverse events (≥5% of patients) occurring in patients with OSA, narcolepsy, or SWD treated with armodafinil (150 or 250 mg/day)</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b40-nss-2-095">40</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b46-nss-2-095">46</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref ref-type="bibr" rid="b55-nss-2-095">55</xref></citation_analysis></p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="2" colspan="1">Indications</th>
            <th align="left" valign="top" rowspan="2" colspan="1">Adverse events</th>
            <th colspan="2" align="left" valign="top" rowspan="1">Incidence (%)</th>
          </tr>
          <tr>
            <th colspan="2" align="right" valign="top" rowspan="1">
<hr/></th>
          </tr>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1"/>
            <th align="left" valign="top" rowspan="1" colspan="1"/>
            <th align="left" valign="top" rowspan="1" colspan="1">Armodafinil (150/250 mg)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Placebo</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="6" colspan="1">
              <bold>OSA</bold>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic> = 391)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic> = 260)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Headache</td>
            <td align="left" valign="top" rowspan="1" colspan="1">17</td>
            <td align="left" valign="top" rowspan="1" colspan="1">8</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
            <td align="left" valign="top" rowspan="1" colspan="1">6</td>
            <td align="left" valign="top" rowspan="1" colspan="1">4</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">insomnia</td>
            <td align="left" valign="top" rowspan="1" colspan="1">6</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Dizziness</td>
            <td align="left" valign="top" rowspan="1" colspan="1">5</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Anxiety</td>
            <td align="left" valign="top" rowspan="1" colspan="1">5</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&lt;1</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="4" colspan="1">
              <bold>Narcolepsy</bold>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic> = 131)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic> = 63)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Headache</td>
            <td align="left" valign="top" rowspan="1" colspan="1">22</td>
            <td align="left" valign="top" rowspan="1" colspan="1">11</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
            <td align="left" valign="top" rowspan="1" colspan="1">11</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Dizziness</td>
            <td align="left" valign="top" rowspan="1" colspan="1">5</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="5" colspan="1">
              <bold>SWD</bold>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic> = 123)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic> = 122)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Headache</td>
            <td align="left" valign="top" rowspan="1" colspan="1">12</td>
            <td align="left" valign="top" rowspan="1" colspan="1">10</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
            <td align="left" valign="top" rowspan="1" colspan="1">7</td>
            <td align="left" valign="top" rowspan="1" colspan="1">3</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Nasopharyngitis</td>
            <td align="left" valign="top" rowspan="1" colspan="1">6</td>
            <td align="left" valign="top" rowspan="1" colspan="1">3</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Anxiety</td>
            <td align="left" valign="top" rowspan="1" colspan="1">5</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn5-nss-2-095">
          <p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> OSA, obstructive sleep apnea; SWD, shift-work disorder.</citation_analysis></p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
